RET mutation analysis. Clinical applications in hereditary and sporatid forms of medullary thyroid carcinoma (MTC);ANALYSE DU GENE RET ET CANCER MEDULLAIRE DE LA THYROIDE. APPORT AU DIAGNOSTIC ET AU TRAITEMENT

Annales d'Endocrinologie

Volumn 57, Issue 1, 1996, Pages 9-14

  Schuffenecker, I ^a   Chambe, B ^a   Lenoir, G ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

medullary thyroid carcinoma; RET mutation

Indexed keywords

CONFERENCE PAPER; HEREDITY; HUMAN; MUTATION; NEUROFIBROMATOSIS; GENETICS; MEDULLARY CARCINOMA; THYROID TUMOR;

PROTEIN TYROSINE KINASE;

CARCINOMA, MEDULLARY; HUMANS; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 0029945122     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. BARBOT N, CALMETTES C, SCHUFFESECKER I et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma of the thyroid, using an immunoradiometric assay of calcitonm : a study of 50 thyroidectomized patients. J Clin Endocrinol Metab 1994 ; 78 : 114-20.
2. BELDJORD C, DESCLAUX-ARAMOND F, RAFFIN-SANSON M et al. The RET protooncogene in sporadic pheochromocytomas : frequent Multiple Endocrine Neoplasias 2-like mutations and new molecular defects. Am J Hum Genet 1994 ; 55 : A51.
3. BOLINO A, SCHUFFENECKER I, LUO Y et al. RET mutations in exons 13 and 14 of MTC patients. Oncogene 1995 ; 10 : 2415-9.
4. CARLSON KM, DOU S, CHI D et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994 ; 91 : 1579-83.
5. DONIS-KELLER H, DOU S, CHI D et al. Mutations in the RET proto-oncoaene are associated with MEN 2A and FMTC. Hum Mol Genet 1993 ; 2 : 851-6.
6. EDERY P, LYONNET S, MULLIGAN L et al. Mutations of the RET protooncogene in Hirschsprung disease. Nature 1994 ; 367 : 378-80.
7. ENG C, SMITH DP, MULLIGAN LM et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995 ; 10 : 509-53.
8. ENG C, SMITH DP, MULLIGAN LM et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neopolasia type 2B and related sporadic tumours. Hum Mol Genet 1994 ; 3 : 237-41.
9. ENG C, MULLIGAN LM, SMITH DP et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 1995 ; 43 : 123-7.
10. ENG C, MULLIGAN LM, SMITH DP et al. Mutation of the RET proto-oncogene in sporadic medullary thyroid carcinoma. Genes Chrom Canc 1995 ; 12 : 209-12.
11. HOFSTRA RMW, LANDSVATER RM, CECCHERINI I et al. Mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994 ; 367 375-6.
12. LANDSVATER RM, ROMBOUTS AGM, TE MEERMAN GJ et al. The clinical implications of a positive calctionin test for C-cell hyperplasia in gentically unaffected members of a MEN 2A kindred. Am J Hum Genet 1993 ; 52 : 335-42.
13. LEDGER GA, KHOSLA S, LINDOR NM et al. Genetic testing in the diagnosis and management, of multiple endocrine neoplasia type 2. Ann Intern Med 1995 ; 122 : 118-24.
14. LIPS CJM, LANDSVATER RM, HOPPENER JWM et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994 ; 29 : 828-35.
15. Mulligan LM, Ponder BAJ. Genetic basis of endocrine disease multiple endocrine enoplasia type 2. J Clin Endocrinol Metab 1995 ; 80 : 1989-95.
16. MULLIGAN LM, KWOK JBJ, HEALEY CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993 ; 363 : 458-60.
17. MULLIGAN LM, ENG C, HEALEY CS et al. Specific mutations of the RET proto-oncogene are related to disease pbenotype in MEN 2A and FMTC. Nature Genetics 1994 ; 6 : 70-4.
18. PACHNIS V, MANKOO BS, COSTANTINI F. Expression of the ret proto-oncogene during mouse embryogenesis. Development 1993 ; 119 : 1005-17.
19. PASSNI B, BORRELLO MG, GRECO A et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nature Genetics 1995 ; 10 : 35-40.
20. ROMEO G, RONCHETTO P, LUO Y et al. Point mutations affecting the tyrosine kinase domain of the RET protooncogene in Hirschsprung disease. Nature 1994 ; 367: 377-8.
21. ROSSEL M, SCHUFFENECKER I, SCHLUMBERGER M et al. Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet 1995 ; 95 : 403-6.
22. SANTORO M, CARLOMAGNO F, ROMANO A et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995 ; 267 : 381-3.
23. SCHUDARDT A, DAGATI V, LARSSON-BIOMBERG L et al. Defect in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET. Nature 1994 ; 367 380-3.
24. SCHUDARDT A, SRINIVAS S PACHNIS V, CONSTANTINI F. Isolation and characterisation of a chicken homolog of the c-ret proto-oncogene. Oncongene 1995 ; 10 : 641-9.
25. SCHUFFENECKER I, BILLAUD M, CALENDER A et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994 ; 3 : 1939-43.
26. THIBODEAU S, LINDOR N, HONCHEL R, KHOSLA S. Mutations in the RET proto-oncogene in sporadic pheochromocytomas. Am J Hum Genet 1994 ; 55 : A71.
27. ZEDENIUS J, WALLIM G, HAMBERGER B et al. Somatic and MEN 2A de novo mutations in the RET proto-oncogene by screening of sporadic MTC. Hum Molec Genet 1994 ; 3 : 1259-62.